Last reviewed · How we verify
NCT05361109
Baricitinib for Cutaneous Dermatomyositis
Phase 2 trial testing Baricitinib in Dermatomyositis. Withdrawn.
31 March 2023
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 June 2022 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Baricitinib (baricitinib) — full drug profile →
Conditions studied
- Dermatomyositis — all drugs for Dermatomyositis →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 2, single-center study in patients with active cutaneous DM who have had an inadequate response. An inadequate response is defined as no improvement with standard of care treatment based on the investigator's opinion. All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected serious adverse events related to baricitinib have occurred during the first 8 weeks of treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16 weeks. Visits are scheduled at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks. Evaluation of primary endpoint occurs at week 24. All subjects receive a phone call from study
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ. · · 2023 · cited 8× · PMID 37158055 · DOI 10.1080/1744666x.2023.2212162 -
Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review.
La Rocca G, Ferro F, Baldini C, Libra A, et al · · 2023 · cited 7× · PMID 36993798 · DOI 10.3389/fmed.2023.1158768 -
Leveraging Genomic and Bioinformatic Analysis to Enhance Drug Repositioning for Dermatomyositis.
Irham LM, Adikusuma W, La'ah AS, Chong R, et al · · 2023 · cited 1× · PMID 37627776 · DOI 10.3390/bioengineering10080890
Verify or expand the search:
- PubMed search for NCT05361109
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Baricitinib
Trials testing the same drug.
- NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07268534 — Biologics in Folliculitis Decalvans : an Adaptative Trial Research · Phase 2 · not yet recruiting
- NCT06923072 — Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement · Phase 2 · recruiting
Other recruiting trials for Dermatomyositis
Currently open trials in the same condition.
- NCT06672822 — Intralesional Injection of STS in Treatment of Calcinosis · Phase 2 · recruiting
- NCT06698796 — A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies · Phase 3 · recruiting
- NCT06732674 — Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases · NA · recruiting
- NCT06686524 — Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refracto · Phase 1 · recruiting
- NCT07037472 — Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treat · NA · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05361109 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 1 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361109.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing